Assessment of the quality of anticoagulation management with warfarin in a tertiary care center

Monirah A. Albabtain; Maha M. Alharthi; Khalid Dagriri; Amr A. Arafat; Esraa Ayrout; Yahya Alhebaishi; Ahmed AlFagih

doi:10.15537/smj.2020.11.25456

References

↵
1. Caldeira D,
2. Cruz I,
3. Morgado G,
4. Stuart B,
5. Gomes C,
6. Martins C,
7. et al.
(2014) Evaluation of time in therapeutic range in anticoagulated patients:a single-center, retrospective, observational study. BMC Res Notes 7:891.
OpenUrl
↵
1. Wigle P,
2. Hein B,
3. Bloomfield HE,
4. Tubb M,
5. Doherty M
(2013) Updated guidelines on outpatient anticoagulation. Am Fam Physician 87:556–566.
OpenUrl PubMed
↵
1. Zhu J,
2. Alexander GC,
3. Nazarian S,
4. Segal JB,
5. Wu AW
(2018) Trends and variation in oral anticoagulant choice in patients with atrial fibrillation 2010-2017. Pharmacotherapy 38:907–920.
OpenUrl CrossRef PubMed
↵
1. Hirsh J,
2. Fuster V,
3. Ansell J,
4. Halperin JL
(2003) American heart association/American college of cardiology foundation guide to warfarin therapy. Circulation 107:1692–1711.
OpenUrl FREE Full Text
↵
1. Gateman D,
2. Trojnar ME,
3. Agarwal G
(2017) Time in therapeutic range:warfarin anticoagulation for atrial fibrillation in a community-based practice. Can Fam Physician 63:e425–e431.
OpenUrl Abstract/FREE Full Text
↵
1. Farsad BF,
2. Abbasinazari M,
3. Dabagh A,
4. Bakshandeh H
(2016) Evaluation of time in therapeutic range (TTR) in patients with non-valvular atrial fibrillation receiving treatment with warfarin in Tehran, Iran:a cross-sectional study. J Clin Diagn Res 10:FC04–FC06.
OpenUrl
↵
1. Lip GYH,
2. Banerjee A,
3. Boriani G,
4. Chiang CE,
5. Fargo R,
6. Freedman B,
7. et al.
(2018) Antithrombotic therapy for atrial fibrillation:CHEST guideline and expert panel report. Chest 154:1121–1201.
OpenUrl
↵
1. Siddiqui S,
2. DeRemer CE,
3. Waller JL,
4. Gujral JS
(2018) Variability in the calculation of time in therapeutic range for the quality control measurement of warfarin. J Innov Card Rhythm Manag 9:3428–3434.
OpenUrl
↵
1. Alyousif SM,
2. Alsaileek AA
(2016) Quality of anticoagulation control among patients with atrial fibrillation:an experience of a tertiary care center in Saudi Arabia. J Saudi Heart Assoc 28:239–243.
OpenUrl
↵
1. Zubaid M,
2. Saad H,
3. Ridha M,
4. Mohanan Nair KK,
5. Rashed W,
6. Alhamdan R,
7. et al.
(2013) Quality of anticoagulation with warfarin across Kuwait. Hellenic J Cardiol 54:102–106.
OpenUrl
1. Fenta TG,
2. Assefa T,
3. Alemayehu B
(2017) Quality of anticoagulation management with warfarin among outpatients in a tertiary hospital in Addis Ababa, Ethiopia:a retrospective cross-sectional study. BMC Health Serv Res 17:389.
OpenUrl
1. Connolly SJ,
2. Pogue J,
3. Eikelboom J,
4. Flaker G,
5. Commerford P,
6. Franzosi MG,
7. et al.
(2008) Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118:2029–2037.
OpenUrl Abstract/FREE Full Text
1. Manji I,
2. Pastakia SD,
3. DO AN,
4. Ouma MN,
5. Schellhase E,
6. Karwa R,
7. et al.
(2011) Performance outcomes of a pharmacist-managed anticoagulation clinic in the rural, resource-constrained setting of Eldoret, Kenya. J Thromb Haemost 9:2215–2220.
OpenUrl CrossRef PubMed
1. Chieffo A,
2. Van Mieghem NM,
3. Tchetche D,
4. Dumonteil N,
5. Giustino G,
6. Van der Boon RM,
7. et al.
(2015) Impact of mixed aortic valve stenosis on VARC-2 outcomes and postprocedural aortic regurgitation in patients undergoing transcatheter aortic valve implantation:results from the international multicentric study PRAGMATIC (pooled Rotterdam-Milan-Toulouse in collaboration). Catheter Cardiovasc Interv 86:875–885.
OpenUrl
1. Kılıç S,
2. Çelik A,
3. Çakmak HA,
4. Afşin A,
5. Tekkeşin Aİ,
6. Açıksarı G,
7. et al.
(2017) The time in therapeutic range and bleeding complications of warfarin in different geographic regions of Turkey:a subgroup analysis of WARFARIN-TR Study. Balkan Med J 34:349–355.
OpenUrl
↵
1. Hakeem H,
2. Khan AZ,
3. Aziz K,
4. Abbasi A,
5. Haider A,
6. Moiz B,
7. et al.
(2018) Evaluation of quality of warfarin therapy by assessing patient's time in therapeutic range at a tertiary care hospital in Pakistan. J Pak Med Assoc 68:1339–1344.
OpenUrl
↵
1. Pokorney SD,
2. Simon DN,
3. Thomas L,
4. Fonarow GC,
5. Kowey PR,
6. Chang P,
7. et al.
(2015) Patients'time in therapeutic range on warfarin among US patients with atrial fibrillation:results from ORBIT-AF registry. Am Heart J 170:141–148.
OpenUrl CrossRef PubMed
↵
1. Inoue H,
2. Kodani E,
3. Atarashi H,
4. Okumura K,
5. Yamashita T,
6. Okuyama Y,
7. et al.
(2018) Time in therapeutic range and disease outcomes in elderly Japanese patients with nonvalvular atrial fibrillation. Circ J 82:2510–2517.
OpenUrl
↵
1. Ge B,
2. Zhang Z,
3. Zuo Z
(2014) Updates on the clinical evidenced herb-warfarin interactions. Evid Based Complement Alternat Med 2014, 957362.
↵
1. Rose AJ,
2. Hylek EM,
3. Ozonoff A,
4. Ash AS,
5. Reisman JI,
6. Berlowitz DR
(2010) Patient characteristics associated with oral anticoagulation control:results of the veterans affairs study to improve anticoagulation (VARIA). J Thromb Haemost 8:2182–2191.
OpenUrl CrossRef PubMed Web of Science
↵
1. Ciurus T,
2. Cichocka-Radwan A,
3. Lelonek M
(2015) Factors affecting the quality of anticoagulation with warfarin:experience of one cardiac centre. Kardiochir Torakochirurgia Pol 12:334–340.
OpenUrl
↵
1. Melamed OC,
2. Horowitz G,
3. Elhayany A,
4. Vinker S
(2011) Quality of anticoagulation control among patients with atrial fibrillation. Am J Manag Care 17:232–237.
OpenUrl PubMed
↵
1. Nelson WW,
2. Choi JC V,
3. anderpoel J,
4. Damaraju CV,
5. Wildgoose P,
6. Fields LE,
7. et al.
(2013) Impact of co-morbidities and patient characteristics on international normalized ratio control over time in patients with nonvalvular atrial fibrillation. Am J Cardiol 112:509–512.
OpenUrl CrossRef PubMed
↵
1. Diken AI,
2. Yalçınkaya A,
3. Hanedan MO,
4. Erol ME,
5. Ercen Diken Ö
(2018) Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment:a cost analysis. Phlebology 33:53–59.
OpenUrl

In this issue

Download PDF

Email Article

Citation Tools

Bookmark this article

Cited By...

Comparing tele-pharmacy and standard clinic follow-up for newly initiated warfarin anticoagulation therapy: A retrospective study

Google Scholar

More in this TOC Section

Show more Original Article

Keywords

[1] ↵
Caldeira D,
Cruz I,
Morgado G,
Stuart B,
Gomes C,
Martins C,
et al.
(2014) Evaluation of time in therapeutic range in anticoagulated patients:a single-center, retrospective, observational study. BMC Res Notes 7:891.
OpenUrl

[2] Caldeira D,

[3] Cruz I,

[4] Morgado G,

[5] Stuart B,

[6] Gomes C,

[7] Martins C,

[8] et al.

[9] ↵
Wigle P,
Hein B,
Bloomfield HE,
Tubb M,
Doherty M
(2013) Updated guidelines on outpatient anticoagulation. Am Fam Physician 87:556–566.
OpenUrl PubMed

[10] Wigle P,

[11] Hein B,

[12] Bloomfield HE,

[13] Tubb M,

[14] Doherty M

[15] ↵
Zhu J,
Alexander GC,
Nazarian S,
Segal JB,
Wu AW
(2018) Trends and variation in oral anticoagulant choice in patients with atrial fibrillation 2010-2017. Pharmacotherapy 38:907–920.
OpenUrl CrossRef PubMed

[16] Zhu J,

[17] Alexander GC,

[18] Nazarian S,

[19] Segal JB,

[20] Wu AW

[21] ↵
Hirsh J,
Fuster V,
Ansell J,
Halperin JL
(2003) American heart association/American college of cardiology foundation guide to warfarin therapy. Circulation 107:1692–1711.
OpenUrl FREE Full Text

[22] Hirsh J,

[23] Fuster V,

[24] Ansell J,

[25] Halperin JL

[26] ↵
Gateman D,
Trojnar ME,
Agarwal G
(2017) Time in therapeutic range:warfarin anticoagulation for atrial fibrillation in a community-based practice. Can Fam Physician 63:e425–e431.
OpenUrl Abstract/FREE Full Text

[27] Gateman D,

[28] Trojnar ME,

[29] Agarwal G

[30] ↵
Farsad BF,
Abbasinazari M,
Dabagh A,
Bakshandeh H
(2016) Evaluation of time in therapeutic range (TTR) in patients with non-valvular atrial fibrillation receiving treatment with warfarin in Tehran, Iran:a cross-sectional study. J Clin Diagn Res 10:FC04–FC06.
OpenUrl

[31] Farsad BF,

[32] Abbasinazari M,

[33] Dabagh A,

[34] Bakshandeh H

[35] ↵
Lip GYH,
Banerjee A,
Boriani G,
Chiang CE,
Fargo R,
Freedman B,
et al.
(2018) Antithrombotic therapy for atrial fibrillation:CHEST guideline and expert panel report. Chest 154:1121–1201.
OpenUrl

[36] Lip GYH,

[37] Banerjee A,

[38] Boriani G,

[39] Chiang CE,

[40] Fargo R,

[41] Freedman B,

[42] et al.

[43] ↵
Siddiqui S,
DeRemer CE,
Waller JL,
Gujral JS
(2018) Variability in the calculation of time in therapeutic range for the quality control measurement of warfarin. J Innov Card Rhythm Manag 9:3428–3434.
OpenUrl

[44] Siddiqui S,

[45] DeRemer CE,

[46] Waller JL,

[47] Gujral JS

[48] ↵
Alyousif SM,
Alsaileek AA
(2016) Quality of anticoagulation control among patients with atrial fibrillation:an experience of a tertiary care center in Saudi Arabia. J Saudi Heart Assoc 28:239–243.
OpenUrl

[49] Alyousif SM,

[50] Alsaileek AA

[51] ↵
Zubaid M,
Saad H,
Ridha M,
Mohanan Nair KK,
Rashed W,
Alhamdan R,
et al.
(2013) Quality of anticoagulation with warfarin across Kuwait. Hellenic J Cardiol 54:102–106.
OpenUrl

[52] Zubaid M,

[53] Saad H,

[54] Ridha M,

[55] Mohanan Nair KK,

[56] Rashed W,

[57] Alhamdan R,

[58] et al.

[59] Fenta TG,
Assefa T,
Alemayehu B
(2017) Quality of anticoagulation management with warfarin among outpatients in a tertiary hospital in Addis Ababa, Ethiopia:a retrospective cross-sectional study. BMC Health Serv Res 17:389.
OpenUrl

[60] Fenta TG,

[61] Assefa T,

[62] Alemayehu B

[63] Connolly SJ,
Pogue J,
Eikelboom J,
Flaker G,
Commerford P,
Franzosi MG,
et al.
(2008) Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118:2029–2037.
OpenUrl Abstract/FREE Full Text

[64] Connolly SJ,

[65] Pogue J,

[66] Eikelboom J,

[67] Flaker G,

[68] Commerford P,

[69] Franzosi MG,

[70] et al.

[71] Manji I,
Pastakia SD,
DO AN,
Ouma MN,
Schellhase E,
Karwa R,
et al.
(2011) Performance outcomes of a pharmacist-managed anticoagulation clinic in the rural, resource-constrained setting of Eldoret, Kenya. J Thromb Haemost 9:2215–2220.
OpenUrl CrossRef PubMed

[72] Manji I,

[73] Pastakia SD,

[74] DO AN,

[75] Ouma MN,

[76] Schellhase E,

[77] Karwa R,

[78] et al.

[79] Chieffo A,
Van Mieghem NM,
Tchetche D,
Dumonteil N,
Giustino G,
Van der Boon RM,
et al.
(2015) Impact of mixed aortic valve stenosis on VARC-2 outcomes and postprocedural aortic regurgitation in patients undergoing transcatheter aortic valve implantation:results from the international multicentric study PRAGMATIC (pooled Rotterdam-Milan-Toulouse in collaboration). Catheter Cardiovasc Interv 86:875–885.
OpenUrl

[80] Chieffo A,

[81] Van Mieghem NM,

[82] Tchetche D,

[83] Dumonteil N,

[84] Giustino G,

[85] Van der Boon RM,

[86] et al.

[87] Kılıç S,
Çelik A,
Çakmak HA,
Afşin A,
Tekkeşin Aİ,
Açıksarı G,
et al.
(2017) The time in therapeutic range and bleeding complications of warfarin in different geographic regions of Turkey:a subgroup analysis of WARFARIN-TR Study. Balkan Med J 34:349–355.
OpenUrl

[88] Kılıç S,

[89] Çelik A,

[90] Çakmak HA,

[91] Afşin A,

[92] Tekkeşin Aİ,

[93] Açıksarı G,

[94] et al.

[95] ↵
Hakeem H,
Khan AZ,
Aziz K,
Abbasi A,
Haider A,
Moiz B,
et al.
(2018) Evaluation of quality of warfarin therapy by assessing patient's time in therapeutic range at a tertiary care hospital in Pakistan. J Pak Med Assoc 68:1339–1344.
OpenUrl

[96] Hakeem H,

[97] Khan AZ,

[98] Aziz K,

[99] Abbasi A,

[100] Haider A,

[101] Moiz B,

[102] et al.

[103] ↵
Pokorney SD,
Simon DN,
Thomas L,
Fonarow GC,
Kowey PR,
Chang P,
et al.
(2015) Patients'time in therapeutic range on warfarin among US patients with atrial fibrillation:results from ORBIT-AF registry. Am Heart J 170:141–148.
OpenUrl CrossRef PubMed

[104] Pokorney SD,

[105] Simon DN,

[106] Thomas L,

[107] Fonarow GC,

[108] Kowey PR,

[109] Chang P,

[110] et al.

[111] ↵
Inoue H,
Kodani E,
Atarashi H,
Okumura K,
Yamashita T,
Okuyama Y,
et al.
(2018) Time in therapeutic range and disease outcomes in elderly Japanese patients with nonvalvular atrial fibrillation. Circ J 82:2510–2517.
OpenUrl

[112] Inoue H,

[113] Kodani E,

[114] Atarashi H,

[115] Okumura K,

[116] Yamashita T,

[117] Okuyama Y,

[118] et al.

[119] ↵
Ge B,
Zhang Z,
Zuo Z
(2014) Updates on the clinical evidenced herb-warfarin interactions. Evid Based Complement Alternat Med 2014, 957362.

[120] Ge B,

[121] Zhang Z,

[122] Zuo Z

[123] ↵
Rose AJ,
Hylek EM,
Ozonoff A,
Ash AS,
Reisman JI,
Berlowitz DR
(2010) Patient characteristics associated with oral anticoagulation control:results of the veterans affairs study to improve anticoagulation (VARIA). J Thromb Haemost 8:2182–2191.
OpenUrl CrossRef PubMed Web of Science

[124] Rose AJ,

[125] Hylek EM,

[126] Ozonoff A,

[127] Ash AS,

[128] Reisman JI,

[129] Berlowitz DR

[130] ↵
Ciurus T,
Cichocka-Radwan A,
Lelonek M
(2015) Factors affecting the quality of anticoagulation with warfarin:experience of one cardiac centre. Kardiochir Torakochirurgia Pol 12:334–340.
OpenUrl

[131] Ciurus T,

[132] Cichocka-Radwan A,

[133] Lelonek M

[134] ↵
Melamed OC,
Horowitz G,
Elhayany A,
Vinker S
(2011) Quality of anticoagulation control among patients with atrial fibrillation. Am J Manag Care 17:232–237.
OpenUrl PubMed

[135] Melamed OC,

[136] Horowitz G,

[137] Elhayany A,

[138] Vinker S

[139] ↵
Nelson WW,
Choi JC V,
anderpoel J,
Damaraju CV,
Wildgoose P,
Fields LE,
et al.
(2013) Impact of co-morbidities and patient characteristics on international normalized ratio control over time in patients with nonvalvular atrial fibrillation. Am J Cardiol 112:509–512.
OpenUrl CrossRef PubMed

[140] Nelson WW,

[141] Choi JC V,

[142] anderpoel J,

[143] Damaraju CV,

[144] Wildgoose P,

[145] Fields LE,

[146] et al.

[147] ↵
Diken AI,
Yalçınkaya A,
Hanedan MO,
Erol ME,
Ercen Diken Ö
(2018) Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment:a cost analysis. Phlebology 33:53–59.
OpenUrl

[148] Diken AI,

[149] Yalçınkaya A,

[150] Hanedan MO,

[151] Erol ME,

[152] Ercen Diken Ö

Main menu

User menu

Search

Assessment of the quality of anticoagulation management with warfarin in a tertiary care center

References

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

CONTENT

JOURNAL

AUTHORS

Main menu

User menu

Search

Assessment of the quality of anticoagulation management with warfarin in a tertiary care center

References

In this issue

Citation Manager Formats

Jump to section

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

CONTENT

JOURNAL

AUTHORS